333 related articles for article (PubMed ID: 28702814)
1. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
[TBL] [Abstract][Full Text] [Related]
6. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.
Han SS; Ten Haaf K; Hazelton WD; Munshi VN; Jeon J; Erdogan SA; Johanson C; McMahon PM; Meza R; Kong CY; Feuer EJ; de Koning HJ; Plevritis SK
Int J Cancer; 2017 Jun; 140(11):2436-2443. PubMed ID: 28073150
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
[TBL] [Abstract][Full Text] [Related]
8. Performance of the cancer risk management model lung cancer screening module.
Flanagan WM; Evans WK; Fitzgerald NR; Goffin JR; Miller AB; Wolfson MC
Health Rep; 2015 May; 26(5):11-8. PubMed ID: 25993046
[TBL] [Abstract][Full Text] [Related]
9. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.
de Koning HJ; Meza R; Plevritis SK; ten Haaf K; Munshi VN; Jeon J; Erdogan SA; Kong CY; Han SS; van Rosmalen J; Choi SE; Pinsky PF; Berrington de Gonzalez A; Berg CD; Black WC; Tammemägi MC; Hazelton WD; Feuer EJ; McMahon PM
Ann Intern Med; 2014 Mar; 160(5):311-20. PubMed ID: 24379002
[TBL] [Abstract][Full Text] [Related]
10. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
11. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
12. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Mar; 160(5):330-8. PubMed ID: 24378917
[TBL] [Abstract][Full Text] [Related]
13. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
14. The United States Preventive Services Task Force recommendations for lung cancer screening.
Blackmon SH; Feinglass SR
Thorac Surg Clin; 2015 May; 25(2):199-203. PubMed ID: 25901563
[TBL] [Abstract][Full Text] [Related]
15. Improving selection criteria for lung cancer screening. The potential role of emphysema.
Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
[TBL] [Abstract][Full Text] [Related]
16. Low-dose computed tomography screening for lung cancer: how strong is the evidence?
Woolf SH; Harris RP; Campos-Outcalt D
JAMA Intern Med; 2014 Dec; 174(12):2019-22. PubMed ID: 25317533
[TBL] [Abstract][Full Text] [Related]
17. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
19. Issues with implementing a high-quality lung cancer screening program.
Mulshine JL; D'Amico TA
CA Cancer J Clin; 2014; 64(5):352-63. PubMed ID: 24976072
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]